|
Outcomes for all patients |
|||
| Azithromycin Group (n = 19) |
Placebo Group (n = 16) |
p-value |
|
|
|
|||
| Mortality-no. (%) |
5 (26.3) |
4 (25) |
0.9 |
| Incidence of BPD-no. (%) |
9 (64.3) |
10 (83.3) |
0.26 |
| Duration of Mechanical Ventilation-median (range) |
10 (1–145) |
16 (1–112) |
0.40 |
| Postnatal-steroid |
6 (31.5) |
10 (62.5) |
0.05 |
| Days of CPAP (range) |
6 ± 7 |
6 ± 6 |
0.84 |
| Grade III or IV IVH-no. (%) |
5 (26) |
5 (33) |
0.65 |
| PVL on HUS-no. (%) |
1 (5) |
3 (19) |
0.20 |
| Abnormal Transaminases (AST) |
0 |
1 |
0.20 |
| Bilirubin Peak |
6.5 ± 2 |
6.3 ± 1.9 |
0.68 |
| Days to full feeds‡ |
18 ± 5 |
18 ± 54 |
0.95 |
| Feeding intolerance*-no. (%) |
5 (26) |
9 (56) |
0.07 |
| Necrotizing Enterocolitis-no. (%) |
0 |
1 (6) |
0.20 |
| Abnormal hearing screen-no. (%) |
0 |
3 (25) |
0.08 |
| Bacterial Infection: |
|||
| Blood-no. (%) |
10 (52) |
6 (38) |
0.35 |
| Urine-no. (%) |
1 (5) |
4 (25) |
0.15 |
| CSF-no. (%) |
0 |
2 (12) |
0.20 |
| Fungal Infection: |
|||
| Blood-no. (%) |
3 (16) |
2 (12) |
0.78 |
| Urine-no. (%) |
0 |
2 (12) |
0.20 |
| CSF-no. (%) |
1 (5) |
0 |
1 |
| Days of Antibiotics§ |
10 ± 10 |
19 ± 21 |
0.10 |
| Caffeine Therapy-no. (%) |
13 (68) |
10 (62) |
0.71 |
| PDA†-no. (%) |
10 (52) |
12 (75) |
0.16 |
| Courses of indomethacin |
0.49 |
||
| Median |
1 |
1 |
|
| Interquartile range |
0–1 |
0–2 |
|
| PDA ligated-no. (%) |
3 (15) |
4 (25) |
0.49 |
| Diuretics-no. (%) |
6 (31) |
8 (50) |
0.26 |
| Days of Diuretics |
14 ± 30 |
21 ± 38 |
0.53 |
| Bronchodilators-no. (%) |
5 (26) |
8 (50) |
0.14 |
| Days of Bronchodilators |
10 ± 25 |
18 ± 24 |
0.34 |
| Hospital days |
67 ± 40 |
78 ± 50 |
0.47 |
|
All data analysis was performed using ANOVA (mean ± sd), except for indomethacin and days of mechanical ventilation, which was analyzed using median test. *Defined as feeds being held for more than 24 hours, while on study. †Confirmed by echocardiogram. ‡Defined as when TPN was discontinued. §Excluding azithromycin. | |||
Ballard et al. Respiratory Research 2007 8:41 doi:10.1186/1465-9921-8-41 |
|||